ToleraCell-002

N/A

Report date: 2023/12/08 20:04:42

Base Information

Drug NameToleraCell-002

Drug Alias NameAllogeneic human deceased donor spleen-derived, CD19 selected, ex vivo expanded, pre-apoptotic leukocyte product(Diabetes Free)ToleraCell-002

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesDiabetes Free Inc

China Registration ClassN/A

Develop Information

Active CompaniesDiabetes Free Inc

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

Other Information

ATC CodeN/A